Literature DB >> 24802166

Suppressor of cytokine signaling (SOCS) 2 attenuates renal lesions in rats with diabetic nephropathy.

Yuehong Zhou1, Chuan Lv2, Can Wu2, Fenqin Chen3, Ying Shao2, Qiuyue Wang4.   

Abstract

Diabetic nephropathy (DN) involves damage to the kidney caused by diabetes. It is characterized by renal hypertrophy, tubular atrophy/dilation and glomerular hyperfiltration. Suppressor of cytokine signaling (SOCS) 2 has recently been indicated to be involved in the pathogenesis of DN, however, the exact regulatory mechanisms remain unclear. This study was conducted to explore the role of SOCS2 in the development and progress of DN in a rat model of streptozocin (STZ)-induced diabetes. Recombinant adenoviruses expressing SOCS2 were used to upregulate the expression of SOCS2 in the kidneys of diabetic rats. Our results demonstrated that intrarenal injection of SOCS2 adenoviruses reduced STZ-induced renal lesions, including renal/glomerular hypertrophy, glomerular hyperfiltration, aberrant inflammation and fibrosis. Increased expression levels of proinflammatory proteins (monocyte chemoattractant protein-1, tumor necrotic factor-alpha and interleukin-6) and profibrotic proteins (transforming growth factor-beta, collagen IV and fibronectin) in the diabetic kidneys were decreased after SOCS2 gene delivery. Additionally, adenovirus-mediated upregulation of renal SOCS2 markedly inhibited STZ-induced phosphorylation increases of Janus kinase (JAK) 2, signal transducer and activator of transcription (STAT) 3, STAT5 and extracellular receptor-activated kinase (ERK) 1/2. In summary, the present research demonstrates that SOCS2 reduces renal lesions associated with diabetes in rats.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Diabetic nephropathy; ERK signaling pathway; JAK/STAT signaling pathway; Renal function; SOCS2

Mesh:

Substances:

Year:  2014        PMID: 24802166     DOI: 10.1016/j.acthis.2014.04.002

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  11 in total

1.  Association of ACE polymorphism and diabetic nephropathy susceptibility.

Authors:  Hongbo Ma; Che Yu; Rong Wang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 2.  JAK inhibition and progressive kidney disease.

Authors:  Frank C Brosius; John Cijiang He
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-01       Impact factor: 2.894

3.  Exploring the mechanisms underlying the therapeutic effect of Salvia miltiorrhiza in diabetic nephropathy using network pharmacology and molecular docking.

Authors:  Lili Zhang; Lin Han; Xinmiao Wang; Yu Wei; Jinghui Zheng; Linhua Zhao; Xiaolin Tong
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

4.  The suppressor of cytokine signalling 2 (SOCS2), traumatic brain injury and microglial/macrophage regulation.

Authors:  Harleen S Basrai; Ann M Turnley
Journal:  Neural Regen Res       Date:  2016-09       Impact factor: 5.135

5.  SOCS2 overexpression alleviates diabetic nephropathy in rats by inhibiting the TLR4/NF-κB pathway.

Authors:  Suxia Yang; Junwei Zhang; Shiying Wang; Xinxin Zhao; Jun Shi
Journal:  Oncotarget       Date:  2017-08-24

Review 6.  Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy.

Authors:  Sandra Rayego-Mateos; José Luis Morgado-Pascual; Lucas Opazo-Ríos; Melania Guerrero-Hue; Cristina García-Caballero; Cristina Vázquez-Carballo; Sebastián Mas; Ana Belén Sanz; Carmen Herencia; Sergio Mezzano; Carmen Gómez-Guerrero; Juan Antonio Moreno; Jesús Egido
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

Review 7.  Nano-sized carriers in gene therapy for renal fibrosis in vivo.

Authors:  Haruhisa Miyazawa; Keiji Hirai; Susumu Ookawara; Kenichi Ishibashi; Yoshiyuki Morishita
Journal:  Nano Rev Exp       Date:  2017-06-13

8.  MicroRNA miR-4709-3p targets Large Tumor Suppressor Kinase 2 (LATS2) and induces obstructive renal fibrosis through Hippo signaling.

Authors:  Zexiang Jiang; Weiping Xia; Guoyu Dai; Bo Zhang; Yang Li; Xiang Chen
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

9.  Inhibitor of IGF1 receptor alleviates the inflammation process in the diabetic kidney mouse model without activating SOCS2.

Authors:  Jiayu Li; Rong Dong; Jiali Yu; Sun Yi; Jingjing Da; Fuxun Yu; Yan Zha
Journal:  Drug Des Devel Ther       Date:  2018-09-11       Impact factor: 4.162

Review 10.  Signaling Pathways Involved in Diabetic Renal Fibrosis.

Authors:  Yuqing Zhang; Xiaomin Kang; Rongrong Zhou; Yuting Sun; Fengmei Lian; Xiaolin Tong
Journal:  Front Cell Dev Biol       Date:  2021-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.